Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 18/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20337373 | 0.85 | ALDH1A1 (0.44) | CD38MEN1ALDH1A1KMT2ATYK2 | |
| SCHEMBL17743227 | 0.85 | ALDH1A1 (0.44) | CD38MEN1ALDH1A1KMT2ATYK2 | |
| SCHEMBL19451990 | 0.85 | CD38 (0.40) | CD38MEN1ALDH1A1KMT2ATYK2 | |
| SCHEMBL21460989 | 0.85 | CD38 (0.40) | CD38MEN1ALDH1A1KMT2ATYK2 | |
| SCHEMBL17743278 | 0.84 | CD38 (0.42) | CD38MEN1ALDH1A1KMT2ATYK2 | |
| SCHEMBL20337375 | 0.84 | CD38 (0.42) | CD38MEN1ALDH1A1KMT2ATYK2 | |
| SCHEMBL21460959 | 0.81 | CD38 (0.41) | CD38MEN1ALDH1A1KMT2ATYK2 | |
| SCHEMBL19452089 | 0.81 | CD38 (0.41) | CD38MEN1ALDH1A1KMT2ATYK2 | |
| SCHEMBL20337497 | 0.80 | CD38 (0.43) | CD38MEN1ALDH1A1KMT2ATYK2 | |
| SCHEMBL17742966 | 0.80 | CD38 (0.43) | CD38MEN1ALDH1A1KMT2ATYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315751-A1 | PYRROLO[1,2-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315751-A1 | PYRROLO[1,2-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, GAA, SNCA | CD38 395/4885MEN1 1916/4885ALDH1A1 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.